[1] 胡琴,刘维,邵宏.药物性肝损伤的药物治疗研究进展.中国临床药理学与治疗学,2016, 21:231-236.
[2] Alempijevic T,Zec S,Milosavljevic T.Drug-induced liver injury:Do we know everything World J Hepatol, 2017,9:491-502.
[3] Björnsson ES,Bergmann OM,Björnsson HK,et al.Incidence,presentation,and outcomes in patients with drug-induced liver injury in the general population of Iceland.Gastroenterology, 2013,144:1419-25,1425.e1-3;quiz e19-20.
[4] Larrey D.Epidemiology and individual susceptibility to adverse drug reactions affecting the liver.Semin Liver Dis, 2002,22:145-155.
[5] de Abajo FJ,Montero D,Madurga M,et al.Acute and clinically relevant drug-induced liver injury:a population based case-control study.Br J Clin Pharmacol, 2004,58:71-80.
[6] Sgro C,Clinard F,Ouazir K,et al.Incidence of drug-induced hepatic injuries:a French population-based study.Hepatology, 2002,36:451-455.
[7] Ou P,Chen Y,Li B,et al.Causes,clinical features and outcomes of drug-induced liver injury in hospitalized patients in a Chinese tertiary care hospital.Springerplus, 2015,4:802.
[8] Li L,Jiang W,Wang J.Clinical analysis of 275 cases of acute drug-induced liver disease.Front Med China, 2007,1:58-61.
[9] Chalasani NP,Hayashi PH,Bonkovsky HL,et al. Practice Parameters Committee of the American College of Gastroenterology.ACG Clinical Guideline:the diagnosis and management of idiosyncratic drug-induced liver injury.Am J Gastroenterol, 2014,109:950-966.
[10] 赵兰兰,张玉.药物性肝损伤的风险评估及诊治进展.国际消化病杂志,2015,35:119-121.
[11] Aithal GP,Watkins PB,Andrade RJ,et al.Case definition and phenotype standardization in drug-induced liver injury.Clin Pharmacol Ther, 2011,89:806-815.
[12] Khoo AL,Tham LS,Lee KH,et al.Acute liver failure with concurrent bupropion and carbimazole therapy.Ann Pharmacother, 2003,37:220-223.
[13] Dragovic S,Vermeulen NP,Gerets HH,et al.Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man.Arch Toxicol, 2016,90:2979-3003.
[14] Russmann S,Kullak-Ublick GA,Grattagliano I.Current concepts of mechanisms in drug-induced hepatotoxicity.Curr Med Chem, 2009,16:3041-3053.
[15] Chalasani N,Björnsson E.Risk factors for idiosyncratic drug-induced liver injury.Gastroenterology, 2010,138:2246-2259.
[16] Sobhonslidsuk A,Poovorawan K,Soonthornworasiri N,et al.The incidence,presentation outcomes,risk of mortality and economic data of drug-induced liver injury from a national database in Thailand:a population-base study.BMC Gastroenterol, 2016,16:135.
[17] Kullak-Ublick GA,Andrade RJ,Merz M,et al.Drug-induced liver injury:recent advances in diagnosis and risk assessment. Gut, 2017,66:1154-1164.
[18] Petros Z,Kishikawa J,Makonnen E,et al.HLA-B(*)57 allele is associated with concomitant anti-tuberculosis and antiretroviral drugs induced liver toxicity in ethiopians. Front Pharmacol, 2017,8:90.
[19] Guo Y,Fan Y,Qiu J,et al.Polymorphisms in CTLA4 influence incidence of drug-induced liver injury after renal transplantation in Chinese recipients.PLoS One, 2012,7:e51723.
[20] Lu RJ,Zhang Y,Tang FL,et al.Clinical characteristics of drug-induced liver injury and related risk factors.Exp Ther Med, 2016,12:2606-2616.
[21] 康燕婕,李恒周,张京,等.药物性肝损伤的易感因素分析.中华临床医师杂志(电子版),2011,05:1748-1749.
[22] Chalasani N,Reddy KRK,Fontana RJ,et al.Idiosyncratic drug induced liver injury in african-americans is associated with greater morbidity and mortality compared to caucasians. Am J Gastroenterol, 2017,112:1382-1388.
[23] Teschke R,Schulze J,Eickhoff A,et al.Drug induced liver injury: can biomarkers assist RUCAM in causality assessment Int J Mol Sci, 2017,18.pii:E803.
[24] 周光德,赵景民,张玲霞,等.药物性肝损伤100例临床病理分析.中华肝脏病杂志,2007,15:212-215.
[25] Danan G,Teschke R.RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci, 2015,17.pii:E14.
[26] Licata A,Minissale MG,Calvaruso V,et al.A focus on epidemiology of drug-induced liver injury:analysis of a prospective cohort.Eur Rev Med Pharmacol Sci, 2017,21(1 Suppl):112-121.
[27] Donati M,Conforti A,Lenti MC,et al;DILI-IT Study Group.Risk of acute and serious liver injury associated to nimesulide and other NSAIDs:data from drug-induced liver injury case-control study in Italy.Br J Clin Pharmacol, 2016,82:238-248.
[28] Zhou Y,Yang L,Liao Z,et al.Epidemiology of drug-induced liver injury in China:a systematic analysis of the Chinese literature including 21,789 patients.Eur J Gastroenterol Hepatol, 2013,25:825-829.
[29] 华碧春,卢榜华.中草药的药物性肝损害.康复学报,2000,10:30-32.
[30] 任张青,王进海,李浩,等.药物性肝损伤临床特征及预后多学科专家共识.世界华人消化杂志,2016,24:1257-1263.
[31] 朱曼,郭代红,史录文,等.抗感染药致药源性肝损伤572例分析.中国药房,2015,26:3663-3666.
[32] Marrone G,Vaccaro FG,Biolato M,et al.Drug-induced liver injury 2017:the diagnosis is not easy but always to keep in mind.Eur Rev Med Pharmacol Sci, 2017,21(1 Suppl):122-134.
[33] Haque T,Sasatomi E,Hayashi PH.Drug-Induced Liver Injury:Pattern Recognition and Future Directions. Gut Liver, 2016,10:27-36. |
